Credit: Alan Kwok OD

Enrolments have commenced for Kiora Pharmaceuticals KIO-201 eyedrop phase 2 trial.

Designed to accelerate natural corneal wound healing in patients with persistent corneal epithelial defect (PCED), characterised by non-healing ocular surface wounds, the drop is a novel form of hyaluronic acid modified to enable enhanced viscoelastic properties and a longer ocular surface resonance time. The trial will evaluate the drop’s capacity to protect the corneal surface and accelerate re-epithelisation, said Kiora.